Sexes Eligible for Study: All
Confirmed diagnosis of Stage III or Stage IV NSCLC and have received = 1 line of prior systemic therapy in the locally advanced or metastatic setting
Have at least 1 resectable lesion to generate TIL
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)
Male or female, = 18 years of age
Body weight > 30 kg
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and estimated life expectancy of = 3 months
Adequate bone marrow function at screening
Adequate organ function at screening
If the patient is of childbearing potential or their partner(s) is of childbearing potential, they must agree to use highly effective method of contraception while on study and for 6 months after receiving all protocol-related therapy.
Other eligibility criteria may apply.
Patients may not have received prior cell therapy
Patients may not have received prior anti PD-1 or anti PD-L1 inhibitors
Active or prior documented autoimmune or inflammatory disorders
History of primary immunodeficiency, history of allogeneic organ transplant that requires therapeutic immunosuppression
Received live or attenuated vaccination within 28 days prior to the start of NMA-LD
History of hypersensitivity to cyclophosphamide, fludarabine, dimethyl sulfoxide (DMSO) or IL-2
Known allergic reaction to antibiotics of the aminoglycoside group (ie, streptomycin, gentamicin)
Mean QT interval = 470 msec
Decreased cardiac function as evidenced by a left ventricular ejection fraction of Uncontrolled intercurrent illness
Patients who have obstructive or restrictive pulmonary disease and have a documented FEV1 (forced expiratory volume in 1 second) of = 60%
Active central nervous system metastases and/or leptomeningeal disease
Current or prior use of immunosuppressive medication within 28 days before the first study treatment
Other exclusion criteria may apply.